Literature DB >> 6601263

Clearance of injected radioactively labelled antibodies to tumour products by liposome-bound second antibodies.

P A Keep, F Searle, R H Begent, G M Barratt, J Boden, K D Bagshawe, B E Ryman.   

Abstract

Liposomes containing anti-goat immunoglobulin were injected 24 h after administration of 125I-labelled goat antibody against the carcinoembryonic antigen (anti-CEA) to groups of nude mice bearing human tumour xenografts, and normal mice. Controls in each group received radioactively labelled anti-CEA only. In liposome-treated mice, blood 125I levels were lower than those of controls 30 min to 24 h after liposome administration, with corresponding accumulation of 125I activity in the liver and spleen for the first 2 h after liposome injection. [14C]Cholesterol or 99mTc labels in the bilayer were eliminated rapidly from the blood, with uptake in the liver and spleen. In xenograft-bearing mice, 125I activity detected in the tumours up to 6 h after liposome injection was identical to that detected in the tumours of controls. However, 24 h after liposome injection a reduction in the tumour concentration of 125I-labelled anti-CEA was obtained, but the tumour/blood radioactivity was still increased. In two mice given 27 mumol lipid, the blood radioactivity count after 24 h was only 5% of that in the controls. In rabbits, 2 h after administration of liposomes containing anti-goat second antibody, the circulating 125I activity had dropped by 28-40%. The results suggest that administration of liposome-entrapped second antibody approximately 2 h prior to external scintigraphy may clear circulating radioactively labelled primary antibody by up to 50%.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6601263

Source DB:  PubMed          Journal:  Oncodev Biol Med        ISSN: 0167-1618


  4 in total

1.  Second antibody for improvement of antibody imaging: liposome-entrapped and free preparations in animal and human studies.

Authors:  H J Begent; K A Chester; K D Bagshawe; P A Keep; F Searle; J Boden; G M Barratt; A J Green; S J Riggs; D F Woodrow
Journal:  Clin Exp Immunol       Date:  1989-11       Impact factor: 4.330

2.  Metabolizable 111In chelate conjugated anti-idiotype monoclonal antibody for radioimmunodetection of lymphoma in mice.

Authors:  M K Haseman; D A Goodwin; C F Meares; M S Kaminski; T G Wensel; M J McCall; R Levy
Journal:  Eur J Nucl Med       Date:  1986

3.  The effect of serum CEA on the distribution and clearance of anti-CEA antibody in a pancreatic tumour xenograft model.

Authors:  R B Pedley; J A Boden; R W Boden; A Green; G M Boxer; K D Bagshawe
Journal:  Br J Cancer       Date:  1989-10       Impact factor: 7.640

4.  Clearance of circulating radio-antibodies using streptavidin or second antibodies in a xenograft model.

Authors:  D Marshall; R B Pedley; J A Boden; R Boden; R H Begent
Journal:  Br J Cancer       Date:  1994-03       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.